title: Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
abstract: OBJECTIVE
  Worldwide, approximately 750,000 new cases of breast cancer are diagnosed annually in premenopausal women with limited economic resources. Longer-term survival benefits from adjuvant therapies in such women with operable breast cancer are unknown.
  
  
  METHODS
  From 1993 to 1999, we recruited 709 premenopausal women with operable breast cancer to a multisite randomized clinical trial of adjuvant oophorectomy and tamoxifen for 5 years or observation and this combined hormonal therapy on recurrence.
  
  
  RESULTS
  With a median follow-up of 7.0 years, disease-free and overall survival were significantly improved with the adjuvant treatment (log-rank P = .0003 and .0002, respectively). Five year disease-free survival (DFS) probabilities of 74% and 61% (95% CI for difference, 7% to 21%) and overall survival (OS) rates of 78% and 71% (95% CI for difference, 1% to 21%) were observed in the adjuvant and observation groups. Ten-year DFS probabilities of 62% and 51% (95% CI for difference, 4% to 22%) and OS probabilities of 70% and 52% (95% CI for difference, 6% to 34%) between adjuvant and observation groups, respectively, were observed. In the subset of estrogen receptor-positive patients, 5-year DFS probabilities were 83% and 61%, and 10-year DFS probabilities were 66% and 47%, while 5-year OS probabilities were 88% and 74%, and 10-year OS probabilities were 82% and 49% in the adjuvant and observation groups, respectively.
  
  
  CONCLUSIONS
  In premenopausal women with operable breast cancer not selected for estrogen receptor status or with estrogen receptor-positive tumors, 5- and 10-year DFS and OS rates are significantly improved following adjuvant oophorectomy and tamoxifen.
authors: Ohio State University, B402 Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA. Richard.Love@osumc.edu
authors: Richard R
authors: RR
authors: Love
authors: Nguyen
authors: N
authors: Van Dinh
authors: Tran Tu
authors: TT
authors: Quy
authors: Nguyen Dieu
authors: ND
authors: Linh
authors: Nguyen Dinh
authors: ND
authors: Tung
authors: Tien-Zhen
authors: TZ
authors: Shen
authors: Erinn M
authors: EM
authors: Hade
authors: Gregory S
authors: GS
authors: Young
authors: David
authors: D
authors: Jarjoura
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010052:Ovariectomy; D017697:Premenopause; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen